



ContextVision

CONTEXTVISION AB SECOND QUARTER 2019

Q2 HIGHLIGHTS

- Highest Q2 sales ever
- First AI-based product released for sale
- Beta tests for Digital Pathology initiated
- Adding more specialist competence to Advisory Board

Q2 FINANCIAL DATA

- Sales of 23.1 MSEK (21.9)
- Operating result of 5.4 MSEK (-1.2) and operating margin of 23.4% (-5.4%)
- Earnings per share of 0.5 (-0.2) SEK



SECOND QUARTER SAW THE RELEASE OF FIRST AI-BASED PRODUCT – RECORD SALES AND DIGITAL PATHOLOGY RIGHT ON TRACK

FREDRIK PALM, THE COMPANY'S CEO COMMENTED:

Sales continue to grow in the second quarter reaching 23,1 MSEK, which is 5,5 percent higher than the same quarter last year and the highest ever sales in a second quarter for the company. The operative result was positive 5,4 MSEK, mainly due to higher capitalization, but also supported by higher sales and positive currency effects. Altumira™, our first AI-based product for X-ray, is now released for sale and the first contract is already signed. Multiple beta-sites are now in preparation for testing our upcoming Digital Pathology product INIFY Prostate™ with installations taking place during the third quarter. INIFY Prostate™ will revolutionize the diagnosis of prostate cancer using deep learning technologies.

R&D UPDATES

In Digital Pathology we continue to rapidly develop our first product, INIFY Prostate™. Main focus in the second quarter has been establishing multiple beta test sites. Digital pathology labs have been identified and we expect to sign agreements, install and start the beta tests during the upcoming quarter. Beta tests will play a key part of the development of the product since it will be used in a clinical setting. In parallel with other activities, we are collecting a set of test data that represents the variations within the prostate pathology space to make sure we release a robust product with significant added value in the fast-developing pathology market.

We exhibited at the 15th European Congress of Digital Pathology (ECDP) conference, held in Warwick, U.K. in April. Demonstrations of the new INIFY Prostate™ 1.0 user interface caught a lot of interest for our upcoming product. The user interface is developed to support pathologists in their daily work with prostate biopsies. The algorithms used in INIFY Prostate™ 1.0 will distinguish between cancer/no cancer on the histopathological images, outline the areas with potential cancer and sort them in a worst-first order to support the pathologist.

We signed an agreement with a large biobank in Europe during the first quarter. In the second quarter, we have made further progress with this partnership and the first pilot project for prostate cancer has been defined. In this partnership we will get access to an extensive amount of image data combined with patient records that will support our long-term strategy to develop a portfolio of products for cancer diagnosis.

We are very happy to announce that Dr. Marilyn Bui from Moffit Cancer Centre of Tampa, Florida, USA is joining our advisory board. Dr. Bui is the president of the Digital Pathology Association (DPA) and works as sarcoma pathologist and researcher. Dr. Bui will be a very valuable addition among our advisors.

Altumira™, our first AI-based image enhancement product for static and dynamic X-ray was released for sale in the second quarter. We have signed one contract and we have a pipeline of potential customers that we expect to materialize into additional signed contracts within 2019.

SALES CONTINUE TO GROW

Sales in Asia continue to grow in the second quarter, growing 9 percent compared to the same quarter last year. The company continues to grow in China and Japan in part from a mix of stock orders and an increased volume run rate from several of the company's customers. Our business in South Korea decreased slightly, but that we consider as normal variation.

Following a weak first quarter, sales in the U.S. increased 30 percent compared to the second quarter of 2018. This was an expected recovery since lower sales in Q1 was mostly related to postponed orders due to contract negotiations. Sales in the region are now in line with our estimates.

Sales in Europe decreased this quarter mainly due to one of our products being phased out with a single customer. This loss has been partly covered by increasing sales with other customers, but we did not manage to cover the entire deficit, resulting in 7 percent lower sales in the region for the second quarter.

Ultrasound for 2D imaging as well as X-ray sales increases in comparison with the second quarter last year. Our MRI sales are significantly higher in this

quarter compared to Q2 last year, since we received additional stock orders from several customers.

SUMMARY

We continue with full focus to enter the digital pathology market, we released our first AI-based product which caught great interest among potential customers, and we continue to see solid sales growth which confirms our market leading position within the medical imaging space.

SECOND QUARTER 2019

OPERATING SEGMENTS

- From January 2018 ContextVision reports its sales, costs and results in two separate operating segments; Business Unit Medical Imaging and Business Unit Digital Pathology. This reflects how the management review and measure the results.
- The Business Unit Medical Imaging comprise research, product development and OEM sales within medical imaging. The product portfolio consists of products developed for a variety of modalities, such as Ultrasound, X-ray, MRI, Mammography, CT and iRV.
- The Business Unit Digital Pathology presently includes research and product development of new products for the growing digital pathology market.

NET SALES AND OPERATING PROFIT

NET SALES

- ContextVisions sales in the second quarter amounted to 23.1 MSEK (21.9 MSEK). This represents an increase of 5.5% compared to the same quarter in 2018.
- All sales in the quarter was generated from the Business Unit Medical Imaging. All sales income is generated outside Sweden and from external sales.
- The currency exchange rates had an average effect on sales of 4.9% during the quarter. There were positive effects from changes in all currencies; EUR, USD and JPY.
- The impact of the IFRS 15 standard on the Group's revenue for Q2 2019 is 0.0 MSEK. As of June 30th, 2019, there are no contract assets or liabilities. The change to the standard does not influence the cash flow.

OPERATING PROFIT AND MARGIN

- ContextVision's operating result in the second quarter was 5.4 MSEK (-1.2), and the operating margin 23.4% (-5.4%).

- Capitalization is recorded as intangible fixed assets only when product development meets certain requirements.
- Capitalized costs of total 7.1 MSEK (1.3 MSEK) for development of two separate products have been recorded during the second quarter; one product within the Business Unit Medical Imaging and one within the Business Unit Digital Pathology. This higher level of capitalization is the result of previous years significant investments in research. The product that has been developed within the Business Unit Medical Imaging was finished and released for sale during the second quarter, and therefore there will be no further capitalization of costs referring to that product.
- Both external and personnel costs were lower in Q2 compared to the same quarter last year. This is partly explained by the higher level of capitalization and partly as an effect of the new accounting standard IFRS 16 leases. The underlying costs are comparable to the same period previous year.

CASH-FLOW AND FINANCING

- The cash flow in the second quarter was 2.5 MSEK (-3.7 MSEK).
- Cash at period end amounted to 39.7 MSEK (37.0).
- Equity at period end amounted to 65.4 MSEK (54.4), giving an equity ratio of 65.1% (72.5%).

FINANCIAL INSTRUMENTS

- The Group's financial instruments consist of cash and bank deposits, accounts receivable (trade), accounts payable, other short-term liabilities relating to operations and derivatives (primarily forward exchange contracts). The fair value of financial instruments approximates the carrying amount as of June 30th, 2019.
- Derivatives refer to currency hedging contracts, which have been valued to market value on the balance sheet day and are included in the level 2 of the valuation hierarchy.
- Net derivative value at the balance sheet date amounts to -816 TSEK.

EMPLOYEES AND MANAGEMENT

- At period end the company had 44 (43) employees of which 20 (22) are dedicated to research and development. 1 employee is located in the USA and 1 in China.

CONTEXTVISION GROUP

- The group consists of ContextVision AB (publ), company registration number 556377-8900 as parent company, and ContextVision Inc Corp registration number 36-4333625 State of Illinois, USA, as a wholly owned subsidiary.
- Operations in the group are conducted primarily in the parent company and consist of research and development, sales, marketing and administrative functions.

RISKS & UNCERTAINTIES

- ContextVision's major risk factors include business risks connected to the general global financial situation, to the level of healthcare investment on different markets, currency exchange risks, the company's ability to recruit and keep qualified employees and the effect of political decisions.
- The company's risk factors are described in more detail in the annual report 2018. The risks and uncertainties have not changed significantly since then.

BASIS OF PREPARATION

- The interim condensed consolidated financial statements for the 2:nd quarter ended June 30th, 2019 have been prepared in accordance with IAS 34 Interim Financial Reporting and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual financial statements as of December 31, 2018. Apart from the changes in accounting principles stated below, there have been no changes in the accounting principles or methods for calculation during the period.

NEW AND CHANGED ACCOUNTING PRINCIPLES

- IFRS 16 replaces IAS 17 from January 1, 2019. According to the new standard, the lessee must report the obligation to pay leasing fees as a lease liability in the balance sheet. The right to use the underlying asset during the lease period is reported as an asset. Depreciation of the asset is reported in the income statement as well as interest on the lease liability.
- The Company has chosen to use the modified retrospective model, which allows comparative figures for periods prior to January 1, 2019 not to be recalculated. IFRS 16 has primarily affected ContextVision through rental agreements for offices. ContextVision has decided to apply the exemption rules for short-term leases and leases where the underlying asset has a low value. These leases are not included in the right-of-use asset or the liability. For further details, please refer to the annual report.
- In the Parent Company, the exception in RFR 2 regarding lease agreements will apply. This means that the Parent Company's principles for accounting of leases is unchanged.

SUBSEQUENT EVENTS

- No significant events have occurred during the period between period-end and date of issuance of this report.

This quarterly report provides a fair and true overview of the company's and the Group's activities, position and results, and describes the risks and uncertainties of significance faced by ContextVision and the companies in the Group.

The Board of Directors and the Chief Executive Officer of ContextVision AB
Stockholm 2019-08-14

This report has not been reviewed by the company's auditors.

PRESENTATION AND REPORTING DATES

This quarterly report will be published on the company's website on the 15th of August 2019.

There will be a video presentation released on the 16th of August, at 09.00 CET.

Please follow the link:

<http://webtv.nu/contextvisionq22019>

Please visit www.contextvision.com for further information, or use shareholderinfo@contextvision.se to send a question directly to management.

REPORTING DATES

Q4 and 12 months 2018	February 21, 2019
-----------------------	-------------------

Annual report available on company's website	April 4, 2019
--	---------------

Q1 result 2019	April 25, 2019
----------------	----------------

Annual General Meeting	May 8, 2019
------------------------	-------------

Q2 result 2019	August 15, 2019
----------------	-----------------

Q3 result 2019	October 24, 2019
----------------	------------------

Q4 and 12 months 2019	February 20, 2020
-----------------------	-------------------

FOR MORE INFORMATION PLEASE CONTACT:

Fredrik Palm, CEO
Phone +46 (0)8 750 35 50

CONTEXTVISION FAST FACTS

- ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence.
- ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world.
- ContextVision are currently developing artificial intelligence-based decision support tools for digital Pathology to support the future of fast and reliable cancer diagnosis.
- The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and South Korea.
- ContextVision is a spin-off from the Image Processing Laboratory at Linköping University, Sweden. The corporate identity was established in 1983 with the first OEM agreement in radiology in 1987.
- The company's share is traded on the Oslo Stock Exchange since 1997, under the ticker COV.

THE COMPANY OFFERS:

- 30 years of experience within software for medical imaging.
- Unprecedented image enhancement for ultrasound, Radiography, Mammography and MRI.
- Continuous reinvestment in R&D that ensures timely and rewarding upgrade paths.
- Strong customer relationships to ensure their success.
- Expert training in image processing for our customers.
- Compatibility across different image formats and major computer platforms.
- ContextVision's technology enables the company's customers to provide superior digital imaging solutions for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users.

CONSOLIDATED INCOME STATEMENT (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Net sales	23 138	21 869	44 201	41 080	90 903
Total revenues	23 138	21 869	44 201	41 080	90 903
Goods for resale	-552	-521	-1 152	-947	-2 224
Other external costs	-4 033	-8 132	-8 597	-16 334	-33 150
Personnel costs	-11 299	-13 134	-21 070	-25 630	-50 130
Depreciation assets	-1 843	-1 264	-3 667	-2 488	-5 029
Write-down of intangible assets	0	0	0	0	-1 669
Operating results	5 411	-1 182	9 715	-4 319	-1 299
Interest income	0	0	0	0	14
Interest cost	-87	-5	-181	-5	-6
Results after financial items	5 324	-1 187	9 534	-4 324	-1 291
Tax	-1 227	-15	-2 144	-7	112
Net results	4 097	-1 203	7 390	-4 331	-1 179
Earnings per share after tax (SEK)	0,53	-0,16	0,96	-0,56	-0,15

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Effect of currency hedging	-42	-12	-580	-675	281
Translation difference	-2	88	33	108	114
Total other comprehensive income	-44	76	-547	-567	395
Net result for the period	4 097	-1 203	7 390	-4 331	-1 179
Total comprehensive income for the period	4 053	-1 127	6 843	-4 898	-784

FINANCIAL HIGHLIGHTS

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Earnings per share after tax (SEK) before/after dilution	0,53	-0,16	0,96	-0,56	-0,15
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	23,4	-5,4	22,0	-10,5	-1,4
Solidity (per cent)	65,1	72,5	65,1	72,5	76,2

DEFINITIONS

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity, where average equity is calculated as the equity at beginning of period plus the equity at end of period divided by two.

Operating margin: Operating income excluding non-recurring items as a percentage of net sales.

Profit margin: Result after financial items as a percentage of net sales.

Solidity (Equity ratio): Equity at period end as a percentage of total assets.

SALES BY REGION (MSEK)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Asia	13,2	12,1	25,7	21,8	49,7
Europe	7,1	7,6	13,7	14,4	30,4
USA	2,8	2,2	4,8	4,9	10,8
Total	23,1	21,9	44,2	41,1	90,9

SALES BY PRODUCT (MSEK)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
XR	3,2	3,0	5,8	5,9	12,8
US 2D	12,9	12,8	26,0	24,2	53,7
US 3D	3,6	4,5	6,0	7,5	16,5
MR	2,6	1,4	5,1	3,0	5,7
Others (iRV, CT, Mammo)	0,8	0,2	1,2	0,5	2,2
Total	23,1	21,9	44,2	41,1	90,9

BUSINESS UNITS / OPERATING SEGMENTS (MSEK)

	BUSINESS UNIT MEDICAL IMAGING		BUSINESS UNIT DIGITAL PATHOLOGY		GROUP TOTAL	
	Q2 2019	Q2 2018	Q2 2019	Q2 2018	Q2 2019	Q2 2018
Net sales	23,1	21,9	0	0	23,1	21,9
Operating expenses	-15,3	-15,6	-2,4	-7,5	-17,7	-23,1
Operating results	7,8	6,3	-2,4	-7,5	5,4	-1,2

	BUSINESS UNIT MEDICAL IMAGING		BUSINESS UNIT DIGITAL PATHOLOGY		GROUP TOTAL	
	6 MONTHS 2019	6 MONTHS 2018	6 MONTHS 2019	6 MONTHS 2018	6 MONTHS 2019	6 MONTHS 2018
Net sales	44,2	41,1	0	0	44,2	41,1
Operating expenses	-29,2	-31,4	-5,3	-14,0	-34,5	-44,4
Operating results	15,0	9,7	-5,3	-14,0	9,7	-4,3

CONSOLIDATED BALANCE SHEET IN SUMMARY (SEK 1000)

	JUNE 30 TH , 2019	JUNE 30 TH , 2018		DEC 31 ST , 2018
Intangible fixed assets	24 329	10 571		11 681
Tangible assets	3 134	3 681		3 353
Right-of-use assets	11 363	0		0
Other financial assets	498	653		323
Inventories	960	1 131		714
Current receivables	20 478	22 007		22 817
Cash and bank	39 704	37 044		37 945
Total assets	100 466	75 087		76 833

Equity	65 406	54 449			58 562
Deferred taxes	924	1 112			968
Non-current lease liabilities	6 572	0			0
Current liabilities	23 650	19 516			17 303
Current lease liabilities	3 914	0			0
Total equity and liabilities	100 466	75 087			76 833

CHANGE IN EQUITY IN SUMMARY (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Opening balance	61 353	55 575	58 562	59 346	59 346
Total comprehensive income for the period	4 053	-1 127	6 843	-4 898	-784
Closing balance	65 406	54 449	65 406	54 449	58 562

CONSOLIDATED STATEMENT OF CASH FLOWS (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Result after financial items	5 324	-1 187	9 536	-4 325	-1 291
Depreciation and write-down of assets	1 843	1 264	3 666	2 489	6 698
Unrealized gain/loss on current investments	-42	-12	-580	-675	281
Income tax paid	-433	-407	-939	-601	397
Cash flow from operating activities before change in working capital	6 692	-343	11 683	-3 112	6 085
Change in working capital					
Increase (-)/decrease (+) inventories	-306	498	-246	-555	-138
Increase (-)/decrease (+) current receivables	3 812	-1 357	2 091	1 642	170
Increase (+)/decrease (-) liabilities	465	-867	4 240	1 108	-998
Cash flow from operating activities	10 663	-2 068	17 768	-918	5 119
Investing activities					
Investments in intangible assets	-7 131	-1 306	-13 946	-1 971	-6 955
Investments in tangible assets	-144	-315	-247	-394	-546
Other financial assets	0	0	1	0	0
Cash flow from investing activities	-7 275	-1 621	-14 192	-2 365	-7 501
Financing activities					
Payments of lease liabilities	-912	0	-1 817	0	0
Cash flow from financing activities	-912	0	-1 817	0	0
Cash flow for the period	2 476	-3 689	1 759	-3 283	-2 382
Change of liquid assets					
Liquid assets at beginning of period	37 228	40 733	37 945	40 327	40 327
Liquid assets at period end	39 704	37 044	39 703	37 044	37 945

PARENT COMPANY INCOME STATEMENT (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Net sales	23 138	21 869	44 201	41 080	90 903
Total revenues	23 138	21 869	44 201	41 080	90 903
Goods for resale	-552	-521	-1 152	-947	-2 224
Other external costs	-5 767	-8 756	-12 030	-17 562	-35 783
Personnel costs	-10 608	-12 556	-19 723	-24 483	-47 663
Depreciation assets	-892	-1 264	-1 764	-2 488	-5 029
Write-down of intangible assets	0	0	0	0	-1 669
Operating results	5 319	-1 228	9 532	-4 400	-1 466
Interest income	0	0	0	0	14
Interest cost	-1	-5	-1	-5	-6
Dividends from group company	0	0	0	0	364
Results after financial items	5 318	-1 233	9 531	-4 405	-1 094
Provision for tax allocation reserve	0	0	0	0	900
Tax	-1 211	0	-2 143	22	18
Net results	4 108	-1 233	7 388	-4 383	-176

PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Effect of currency hedging	-42	-12	-580	-675	281
Total other comprehensive income	-42	-12	-580	-675	281
Net result for the period	4 108	-1 233	7 388	-4 383	-176
Total comprehensive income for the period	4 066	-1 245	6 808	-5 058	105

FINANCIAL HIGHLIGHTS

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	23,0	-5,6	21,6	-10,7	-1,6
Solidity (per cent)	68,4	65,8	68,4	65,8	70,9

DEFINITIONS

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity, where average equity is calculated as the equity at beginning of period plus the equity at end of period divided by two.

Operating margin: Operating income excluding non-recurring items as a percentage of net sales.

Profit margin: Result after financial items as a percentage of net sales.

Solidity (Equity ratio): Equity at period end as a percentage of total assets.

SALES BY REGION (MSEK)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Asia	13,2	12,1	25,7	21,8	49,7
Europe	7,1	7,6	13,7	14,4	30,4
USA	2,8	2,2	4,8	4,9	10,8
Total	23,1	21,9	44,2	41,1	90,9

SALES BY PRODUCT (MSEK)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
XR	3,2	3,0	5,8	5,9	12,8
US 2D	12,9	12,8	26,0	24,2	53,7
US 3D	3,6	4,5	6,0	7,5	16,5
MR	2,6	1,4	5,1	3,0	5,7
Others (iRV, CT, Mammo)	0,8	0,2	1,2	0,5	2,2
Total	23,1	21,9	44,2	41,1	90,9

PARENT COMPANY BALANCE SHEET IN SUMMARY (SEK 1000)

	JUNE 30 TH 2019	JUNE 30 TH 2018		DEC 31 ST 2018
Intangible fixed assets	24 329	10 571		11 681
Tangible assets	3 134	3 681		3 353
Other financial assets	715	870		540
Inventories	960	1 131		714
Current receivables	21 441	21 983		22 817
Cash and bank	38 995	36 708		37 783
Total assets	89 574	74 944		76 888
Equity	61 313	49 342		54 505
Untaxed reserves	4 200	5 100		4 244
Current liabilities	24 061	20 502		18 139
Total equity and liabilities	89 574	74 944		76 888

CHANGE IN EQUITY IN SUMMARY (SEK 1000)

	Q2 2019	Q2 2018	SIX MONTHS 2019	SIX MONTHS 2018	FULL YEAR 2018
Opening balance	57 247	50 586	54 505	54 400	54 400
Total comprehensive income for the period	4 066	-1 245	6 808	-5 058	105
Closing balance	61 313	49 342	61 313	49 342	54 505

GLOSSARY

ALTUMIRA

ContextVision's next generation image enhancement for X-ray systems. Altumira is designed with AI (deep learning) technology in combination with ContextVision's leading GOP technology.

ARTIFICIAL INTELLIGENCE (AI)

Artificial Intelligence is the intelligence exhibited by machines or software.

DEEP LEARNING

Deep learning is the latest very powerful technology within machine learning; machine learning with deep neural networks.

DIGITAL PATHOLOGY

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

GOP® (GENERAL OPERATOR PROCESSOR)

ContextVision's methodology and technology base for image analysis and image enhancement, detecting structures in an image and relating them to their wider context in order to increase visualization accuracy.

GOPICE® (IMAGE CUBICLE ENHANCMENT)

ContextVision's real-time 3D volumetric image enhancement product, for OEM embedded software.

GOPVIEW® / PLUSVIEW®

The family names for ContextVision's 2D product lines of OEM-embedded software.

HANDHELD ULTRASOUND

A small ultrasound unit that can be held in the hand when performing the examination, e.g. smartphones and tablet-based systems.

IMAGE ANALYSIS

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

IMAGE PROCESSING

A generic term used to describe the computation of digital images, typically to enhance or analyze them.

IMAGE ENHANCEMENT

To improve the visual quality of a digital image by increasing the visibility of relevant structures, as in edge/contrast enhancement and the suppression of noise or artifacts.

MACHINE LEARNING

Machine learning is the study of computer algorithms that improve automatically through experience.

MAMMOGRAPHY

An X-ray method used to examine the human breast.

MODALITY

A device that generates internal images of the body, such as X-ray, ultrasound, magnetic resonance imaging, and computed tomography.

MRI (MAGNETIC RESONANCE IMAGING)

A non-invasive procedure, generated by variations in strong magnetic fields, that produces a two-dimensional view of an internal organ or structure, especially the brain and spinal cord.

OEM

The acronym for Original Equipment Manufacturer.

REALICE™

REALiCE is a volume enhancement and rendering product package for 3D and 4D fetal volume visualization.

US (ULTRASOUND)

A procedure in which high-energy sound waves are bounced off internal tissues or organs to create echoes. The echo patterns are displayed on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.

VOLARVIEW™

ContextVision's image enhancement product for handheld ultrasound units.

XR (X-RAY)

A diagnostic device in which radiation is used to create images for examination of soft and hard tissue, such as muscle and bone.



ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

As an industry pioneer for more than 30 years, ContextVision is significantly investing in R&D to develop new applications of the latest artificial intelligence technologies and expanding into the growing digital pathology market. The release of its first product, supporting the diagnosis of prostate cancer, is planned in the near future.

The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.

→ FOR MORE INFORMATION, PLEASE VISIT WWW.CONTEXTVISION.COM